Clinical Trial Update: DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating DYME (DY001) as a selective anterior capsule staining agent for cataract surgery has completed, assessing safety and effectiveness.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• DYME (DY001)

Snippet

Sponsor: Aqumen Biopharmaceuticals, N.A. | Conditions: Mature Cataracts | Phase 3 | Status: COMPLETED